Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022

BUY
$3.5 - $6.9 $54,043 - $106,542
15,441 New
15,441 $6,000
Q1 2022

May 17, 2022

SELL
$4.6 - $7.8 $172,486 - $292,476
-37,497 Closed
0 $0
Q4 2021

Feb 17, 2022

BUY
$6.1 - $10.2 $228,731 - $382,469
37,497 New
37,497 $25,000
Q3 2021

Nov 12, 2021

SELL
$8.2 - $12.4 $408,195 - $617,272
-49,780 Closed
0 $0
Q2 2021

Sep 17, 2021

BUY
$11.8 - $18.2 $587,404 - $905,996
49,780 New
49,780 $59,000
Q1 2021

May 19, 2021

SELL
$15.2 - $25.0 $3.45 Million - $5.67 Million
-226,837 Closed
0 $0
Q4 2020

Feb 24, 2021

BUY
$11.2 - $27.7 $2.54 Million - $6.28 Million
226,837 New
226,837 $472,000

About Cellectar Biosciences, Inc.


  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $9.17M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.